Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

Study Overview

• Status: Terminated
• Conditions: Mantle Cell Lymphoma Recurrent; Mantle Cell Lymphoma Refractory; Small Lymphocytic Lymphoma, Relapsed; Waldenstrom's Macroglobulinemia Recurrent; Follicular B-cell Non-Hodgkin's Lymphoma; B-cell Lymphoma Refractory; Waldenstrom's Macroglobulinemia Refractory; Chronic Lymphoid Leukemia in Relapse
• Intervention / Treatment: Biological: MB-106

Detailed Description

This is a multicenter, Phase 1/2, open-label, non-randomized study of MB-106 in patients ≥18 years of age with selected CD20-expressing malignancies.

In both the Phase 1 and Phase 2 portions of the study, all patients must have evidence of CD20 expression.

In Phase 1, patients will be enrolled in 1 of 3 arms, based on their primary diagnosis, as follows:

• Arm 1: Patients with aggressive B-cell non-Hodgkin lymphoma (NHL) including, but not limited to, diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
• Arm 2: Patients with indolent NHL including, but not limited to, follicular lymphoma (FL).
• Arm 3: Patients with chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL).

In Phase 1, escalating MB-106 dose levels will be tested independently in each arm using a 3+3 design.

A total of up to 18 patients are anticipated to be treated in each independent arm in Phase 1, including 6 patients at the maximum tolerated dose (MTD; highest dose level at which ≤1 of 6 patients experiences a dose-limiting toxicity [DLT]), prior to proceeding to the Phase 2 portion of the study for each respective arm, where a total of up to 71 patients will participate in each independent arm.

An assessment of the safety and tolerability of the dose will be made by the Safety Review Committee (SRC) based on the data from the 28-day DLT observation period.

An SRC composed of Principal Investigators and Sponsor representatives will review the safety of each dose level for each arm prior to enrollment at the next dose level in the Phase 1 dose escalation part of study. This process will be repeated for each dose level within each arm until the MTD has been reached, and the recommended Phase 2 dose (RP2D) has been established for that arm.

In Phase 2, the following specific arms of relapsed or refractory CD20-positive B-cell NHL or CLL patients will be treated with MB-106 at the respective RP2D for each arm. Each arm will initially include up to 20 patients:

• Arm 1 Expansion (E): Relapsed or refractory DLBCL, including high-grade B-cell lymphoma with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements, primary mediastinal large B-cell lymphoma and transformed FL.
• Arm 2E: Relapsed or refractory FL.
• Arm 2E-Basket: Relapsed or refractory B-cell NHL subtypes that have progressed after available therapies. This "basket" arm will include but will not be limited to MCL, marginal zone lymphoma (MZL), Waldenstrom's macroglobulinemia (WMG), Burkitt and Burkitt-like lymphoma, and hairy cell leukemia (HCL).
• Arm 3E: Relapsed or refractory CLL/SLL

Arms 1E, 2E and 3E of Phase 2 will have an interim efficacy analysis for futility prior to completion of recruitment to the arm. Arm 2E-Basket will be summarized descriptively only. Safety data from all arms will also be provided at this interim timepoint to the Data Safety Monitoring Board (DSMB) for review. Based on the results of the interim analysis, an additional 51 patients may be added to each of these arms.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Orange, California, United States, 92868-3201
      • UC Irvine Health - Chao Family Comprehensive Cancer Center
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital (MGH)
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center
    • Rochester, New York, United States, 14642
      • University of Rochester Medical Center
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic
  • Washington
    • Seattle, Washington, United States, 98109
      • Fred Hutchinson Cancer Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. For Phase 1: Patient must have relapsed or refractory B-cell NHL (with the exception of Burkitt lymphoma and lymphoblastic lymphoma) or CLL that has progressed after standard therapies, including chemotherapy and anti-CD20 antibody combinations and molecularly targeted therapies. Patients may also have undergone prior stem cell transplant and/or prior CD19-directed CAR-T cell therapy.

2. For Phase 2: Patient must have the following:

   • Arm 1E: Relapsed or refractory DLBCL, including high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, primary mediastinal large B-cell lymphoma and transformed FL. All patients must have progressed after at least 2 lines of therapy, including induction therapy with an anthracycline-based regimen with anti-CD20 antibody, as well as a second systemic therapy. Patients may have also received prior stem cell transplant and/or CD19-directed CAR-T therapy.
   • Arm 2E: Relapsed or refractory FL. All patients must have progressed after at least 2 lines of therapy. Patients may have also received prior stem cell transplant and/or CD19-directed CAR-T therapy.
   • Arm 2E-Basket: Relapsed or refractory B-cell NHL subtypes that have progressed after available therapies. This "basket" arm will include but is not limited to MCL, MZL, WMG, Burkitt and Burkitt-like lymphoma, and HCL. Patients may have also received prior stem cell transplant and/or CD19-directed CAR-T therapy.
   • Arm 3E: Relapsed or refractory CLL/SLL All patients must have progressed after prior Bruton's tyrosine kinase (BTK) and/or BCL-2 directed therapy. Patients may have also progressed or have been intolerant to prior BTK and anti-CD20 antibody therapy. Patients may have also received prior stem cell transplant and/or CD19 CAR-T therapy.
3. For patients treated with prior CD19-directed CAR-T therapy (all arms): relapsed from PR or CR of ≥ 3 months' duration with CD19-positive or -negative disease, or relapsed from PR or CR at any time with CD19-negative disease.
4. For patients treated with prior CD19-directed CAR-T therapy, the peripheral blood absolute CD19+ B-cell count, as measured by flow cytometry, has recovered to at least 20 cells/μl.
5. For patients with NHL, at least 1 measurable lesion according to the revised International Working Group Response Criteria for Malignant Lymphoma. Patients with Waldenstrom macroglobulinemia may qualify for enrollment based on a measurable lesion or an elevated IgM level >0.5 g/dL.
6. For patients with CLL, diagnosis of CLL that meets published diagnostic criteria. Measurable disease is not required.
7. Evidence of CD20 expression on the tumor specimen obtained from the original diagnostic biopsy or another tissue biopsy performed prior to enrollment into this study.
8. At least 2 weeks or 5 half-lives, whichever is shorter, have elapsed since any prior non-investigational systemic therapy before the patient's planned leukapheresis, with the exception of prior BTK inhibitor therapy, which can continue until day -6 (1 day prior to lymphodepletion). At least 6 months have elapsed since the last administration of bendamustine before patient's planned leukapheresis.
9. Males and females ≥18 years of age at the time of consent.
10. Capable of understanding, willing to comply with, and voluntarily sign and date an informed consent form prior to the conduct of any study related assessments/procedures.
11. Able to adhere to the study visit schedule and other protocol requirements.
12. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
13. Life expectancy of ≥ 16 weeks, as assessed by the Principal Investigator.

14. All patients must meet all of the following laboratory criteria unless, in the opinion of the Investigator, the cytopenias are considered to be the result of bone marrow infiltration by lymphoma/CLL:

    • Absolute neutrophil count (ANC) ≥ 0.75×10e9/L.
    • Platelet count ≥ 75×10e9/L.
    • Hemoglobin ≥ 8.5 g/dL.
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5× the upper limit of normal (ULN).
    • Calculated creatinine clearance ≥ 45.0 mL/minute as estimated by Cockcroft-Gault formula.
    • Total bilirubin ≤ 1.5×upper limit of normal (ULN), unless due to suspected Gilbert's syndrome.
15. Adequate pulmonary function, defined as ≤ Grade 1 dyspnea and oxygen saturation (SaO2) ≥ 92% on room air. If pulmonary function tests (PFTs) are performed based on the clinical judgment of the treating physician, patients with forced expiratory volume in 1 second (FEV1) ≥ 50% of predicted and diffusing capacity for carbon monoxide (DLCO) (corrected) of ≥ 40% of predicted will be eligible.
16. Left ventricular ejection fraction ≥ 50%, as determined by echocardiography (ECHO) or multi-gated acquisition scan (MUGA).
17. Females of childbearing potential must have a negative serum or urine pregnancy test at screening and a negative serum or urine pregnancy test prior to initiation of the lymphodepletion regimen.
18. If procreative potential exists, patient must agree to use a highly effective method of contraception from the start of the study until 1 year after the completion of lymphodepletion for females and 4 months after completion of lymphodepletion for males.

Exclusion Criteria:

• Patients who meet ANY of the following criteria will be excluded from the study. No exemptions will be granted.:

  1. Previous treatment with anti-CD20 or anti-CD19 therapy (including antibodies, antibody-drug conjugates [ADCs], bispecific antibodies, etc.) or any investigational agent within 4 weeks before leukapheresis.
  2. Concurrent known additional malignancy that is progressing and/or requires active treatment. Exceptions include squamous or basal cell carcinoma of the skin, superficial bladder cancer, and prostate cancer not requiring treatment.
  3. Presence of active acute or chronic Graft versus Host Disease (GVHD).
  4. Active central nervous system (CNS) lymphoma, including primary CNS lymphoma.
  5. Corticosteroid dependence on doses greater than physiological replacement, i.e., requirement for prednisone > 7.5 mg/day or hydrocortisone ≥ 12 mg/m2/day.
  6. Ongoing prior therapy-related toxicities ≥ Grade 2, according to the Common Toxicity Criteria for Adverse Events (CTCAE), version 5.0, with the exception of alopecia or vitiligo or Grade 2 peripheral neuropathy.

  7. Active systemic infections, active, uncontrolled coagulation or bleeding disorders, or other active, uncontrolled major medical illnesses of the respiratory or immune system.

     • Simple upper respiratory tract infection, uncomplicated bacterial pharyngitis and/or urinary tract infection are permitted if responding to active treatment and after consultation with the study Medical Monitor.
  8. Cardiac involvement with lymphoma, including pericardial involvement and malignant pericardial effusion.
  9. Significant cardiovascular diseases within the past 6 months including uncontrolled congestive heart failure (>New York Heart Association class II), myocardial infarction, unstable angina, or uncontrolled arrhythmia. However, patients with ischemic heart disease who have had acute coronary syndrome, myocardial infarction and/or revascularization > 6 months before Screening, who are without cardiac symptoms, may enroll.
  10. Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression.
  11. Documented human immunodeficiency virus (HIV) infection or any form of primary immunodeficiency, such as severe combined immunodeficiency disease.
  12. Known active infection with hepatitis B, hepatitis C, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or other viral infections requiring systemic therapy.
  13. History of autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the previous 2 years.
  14. If female, pregnant, planning to become pregnant, or breastfeeding.
  15. Any other clinically significant medical disease or condition that, in the Principal Investigator's opinion, may interfere with protocol adherence or the patient's ability to provide informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1: Patients with aggressive B-cell NHL including, but not limited to, DLBCL and MCL.; MB-106, single intravenous infusion up to 3.3 x 10e7 chimeric antigen receptor t-cells (CAR-T cells)/kg	Biological: MB-106; T-cells derived from autologous leukapheresis that are genetically modified.
Experimental: Phase 1: Patients with indolent NHL including, but not limited to, FL.; MB-106, single intravenous infusion up to 3.3 x 10e7 CAR-T cells/kg	Biological: MB-106; T-cells derived from autologous leukapheresis that are genetically modified.
Experimental: Phase 1: Patients with CLL/small lymphocytic lymphoma (SLL).; MB-106, single intravenous infusion up to 3.3 x 10e7 CAR-T cells/kg	Biological: MB-106; T-cells derived from autologous leukapheresis that are genetically modified.
Experimental: Phase 2: Patients with relapsed or refractory DLBCL; MB-106, single intravenous infusion. Dose based upon outcome Phase 1.	Biological: MB-106; T-cells derived from autologous leukapheresis that are genetically modified.
Experimental: Phase 2: Relapsed or refractory FL; MB-106, single intravenous infusion. Dose based upon outcome Phase 1.	Biological: MB-106; T-cells derived from autologous leukapheresis that are genetically modified.
Experimental: Phase 2: Basket - Relapsed or refractory B-cell NHL subtypes; MB-106, single intravenous infusion. Dose based upon outcome Phase 1.	Biological: MB-106; T-cells derived from autologous leukapheresis that are genetically modified.
Experimental: Phase 2: Relapsed or refractory CLL/SLL; MB-106, single intravenous infusion. Dose based upon outcome Phase 1.	Biological: MB-106; T-cells derived from autologous leukapheresis that are genetically modified.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: Primary objective	The safety, tolerability, and feasibility of MB-106 in patients with relapsed or refractory CD20+ B-cell NHL or CLL. Incidence of treatment-emergent AEs (TEAEs) as assessed by CTCAE v5.0, including serious adverse events (SAEs), therapy-related AEs, Grade 3 or 4 TEAEs, TEAEs with an outcome of death (i.e., Grade 5 TEAEs), and TEAEs leading to study discontinuation.	24 months
Phase 1: Primary objective	To determine the RP2D of MB-106 in each of the 3 arms in patients with relapsed or refractory CD20+ B-cell NHL or CLL. The RP2D will be the highest MB-106 dose in each arm that is associated with fewer than 2 cases of DLT in 6 patients.	24 months
Phase 2: Primary objective	To assess the efficacy of MB-106 as measured by objective response rate (ORR) according to the Lugano Classification for Lymphomas for patients with NHL. For patients with CLL, ORR will be assessed according to the 2018 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group. ORR will be determined by the percentage of patients achieving complete remission (CR) or partial remission (PR) as their best response. Radiology scans will be assessed for response by an Independent Central Reviewer.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 2: Secondary objective	Total number of patients with minimal residual disease (MRD) in CLL patients.	24 months
Phase 1: Secondary objective	To assess the efficacy of MB-106 as measured by objective response rate (ORR) according to the Lugano Classification for Lymphomas for patients with NHL. For patients with CLL, ORR will be assessed according to the 2018 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group for patients with CLL. ORR will be determined by percentage of patients achieving complete remission (CR) or partial remission (PR) as their best response.	24 months
Phase 1: Secondary objective	To assess the efficacy of MB-106, as measured by duration of response (DOR), progression-free survival (PFS), and overall survival (OS).	24 months
Phase 1: Secondary objective	To assess the total number of patients with minimal residual disease (MRD) in CLL patients.	24 months
Phase 2: Secondary objective	To assess the efficacy of MB-106, as measured by duration of response (DOR), progression-free survival (PFS), and overall survival (OS).	24 months
Phase 2: Secondary objective	To assess the safety, tolerability, and feasibility of MB-106 in patients with relapsed or refractory CD20+ B-cell NHL or CLL. Incidence of treatment-emergent AEs (TEAEs) as assessed by CTCAE v5.0, including serious adverse events (SAEs), therapy-related AEs, Grade 3 or 4 TEAEs, TEAEs with an outcome of death (i.e., Grade 5 TEAEs), and TEAEs leading to study discontinuation.	24 months

Collaborators and Investigators

• Sponsor: Mustang Bio
• Collaborators: National Cancer Institute (NCI)
• Investigators: Study Chair: Mazyar Shadman, MD, Fred Hutchinson Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): May 24, 2022
• Primary Completion (Actual): April 12, 2024
• Study Completion (Actual): April 12, 2024

Study Registration Dates

• First Submitted: April 14, 2022
• First Submitted That Met QC Criteria: April 29, 2022
• First Posted (Actual): May 4, 2022

Study Record Updates

• Last Update Posted (Actual): July 22, 2024
• Last Update Submitted That Met QC Criteria: July 18, 2024
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease Attributes; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Neoplasms, Plasma Cell; Leukemia, B-Cell; Chronic Disease; Lymphoma; Lymphoma, B-Cell; Leukemia; Recurrence; Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid
• Other Study ID Numbers: MB106-CD20-001; 1R44CA265616-01 (U.S. NIH Grant/Contract)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No